What is DNTH (DNTH) stock price today?

DNTH (DNTH) is currently trading at $106.62, up 0.96% today.

What is DNTH P/E ratio?

DNTH's P/E ratio is -812.38. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is DNTH return on equity (ROE)?

DNTH's return on equity (ROE) is -3.51%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is DNTH's market cap?

DNTH has a market capitalization of $5.96B.

NASDAQ · Biotechnology

DNTH (DNTH) Stock

$106.62 +0.96% NASDAQ: DNTH Healthcare

Valuation

Metric	Value
Price	$106.62
Market Cap	$5.96B
P/E Ratio	-812.38
P/B Ratio	5.05
P/S Ratio	3102.54
EPS (TTM)	$-4.23
52-Week High	$117.88
52-Week Low	$23.39
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-3.51%
ROA	-2.47%
ROCE	-18.48%
Gross Margin	100.00%
Operating Margin	-100.50%
Net Margin	-8.48%
Debt/Equity	0.00
Current Ratio	29.25

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$1.0M	$6.0M	$3.0M	$6.0M	$2.0M
Operating Profit	$-13.0M	$-30.0M	$-48.0M	$-102.0M	$-178.0M
Net Profit	$-13.0M	$-28.0M	$-44.0M	$-85.0M	$-162.0M
EPS	$-3.82	$-7.60	$-8.45	$-2.55	$-4.20
Op Margin	-886.6%	-462.9%	-1704.7%	-1633.7%	-8739.3%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$190.0M	$83.0M	$179.0M	$374.0M	$531.0M
Total Liabilities	$17.0M	$9.0M	$11.0M	$22.0M	$38.0M
Cash	$132.0M	$15.0M	$132.0M	$23.0M	$51.0M
Borrowings	$0	$1.0M	$1.0M	$1.0M	$1.0M

Latest News

Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire · Jul 2, 2026 Dianthus Therapeutics Begins Phase 3 Trial of Treatment for Rare Autoimmune Disorder MT Newswires · Jun 29, 2026 Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis GlobeNewswire · Jun 29, 2026 Chronic Inflammatory Demyelinating Polyneuropathy Market Gains Traction During the Forecast Period (2026-2036) with Advancing Clinical Research Activities | DelveInsight PR Newswire · Jun 18, 2026 DNTH Shares Surge 89% Over the Past Six Months: What's Driving It? Zacks · Jun 17, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-60.0M	$-29.0M	$-37.0M	$-78.0M	$-129.0M
Investing Cash Flow	$42.0M	$-60.0M	$20.0M	$-287.0M	$-123.0M
Financing Cash Flow	$0	$-3.0M	$62.0M	$-14.0M	$0
Net Cash Flow	$73.0M	$8.0M	$117.0M	$-109.0M	$28.0M
Free Cash Flow	$-61.0M	$-29.0M	$-37.0M	$-78.0M	$-129.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	134.11
EV / EBITDA	-196.47
FCF Yield	-2.64%
Quick Ratio	26.10
Interest Coverage	0.00
Return 1Y	326.60%
Return 3Y	770.39%
Return 5Y	10.66%

Ownership

Insiders Held0.13%

Institutions Held121.20%

Institutions Float Held121.36%

Institutional Holder	Shares	Report Date
FMR, LLC	7,767,686	2026-03-31
Blackrock Inc.	3,175,703	2026-03-31
RA Capital Management, L.P.	2,611,733	2026-03-31
Wellington Management Group, LLP	2,595,783	2026-03-31
Fairmount Funds Management LLC	2,537,191	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ANAB	$55.28	-3.07%	-127.70	$1.64B	0.00%
ATAI	$7.34	+0.00%	-8.44	$2.72B	0.00%
BBOT	$8.82	+0.23%	-3.62	$706.54M	0.00%
ELVN	$57.86	-0.05%	-34.70	$4.13B	0.00%
IMTX	$9.43	-1.05%	-4.98	$1.26B	0.00%

About DNTH

DNTH stock trades at $106.62 with a market capitalization of $5.96B. The stock is valued at a price-to-earnings (P/E) ratio of -812.38, price-to-book of 5.05, price-to-sales of 3102.54. Over the past 52 weeks the stock has ranged between $23.39 and $117.88, and currently trades 9.6% below its 52-week high.

On profitability, DNTH generates a return on equity (ROE) of -3.51%, return on capital employed of -18.48%, an operating margin of -100.50%, a net profit margin of -8.48%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides